Specifically, EGFR driver mutations, such as L858R (LR) and deletions in exon 19 (ex19del), are commonly found in non‐small cell lung cancer (NSCLC), and tumors harboring these mutations are especially responsive to treatment with small‐molecule tyrosine kinase inhibitors (TKIs) [12, 13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.